-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
Vaccinated Singaporeans who drop dead suddenly (#DiedSuddenly)
- Thread starter tobelightlight
- Start date
And we don't need compensations.
We need public hangings. The punishment fits the crime.
In Malaysia, Bumiputera has their rights while in Singapore, every Singaporean is seen as a coolie.
no lah, the white cheebais won't uplorry. they are waiting for you to vote them in again. finished eating, now waiting to get another 4 years. Money cannot eat finished one
Last edited:
They already found a solution to increase the population and to increase their votes every election.
They probably all pak saline water to wayang only lah...
They were the salesmen of jewish jabs and the engineers for 4th Industrial Revolution. Most likely were put on exclusion list from the cull. AI will ignore them and will not target them
Meh Meh pak pak
https://australianseniorsnews.com.au/health/new-covid-vaccine-promises-longer-immunity/
New COVID vaccine promises longer immunity
June 5, 2024
Scientists from Monash University and the National University of Singapore have engineered a COVID-19 vaccine that, in pre-clinical models, has shown very long-lasting, protective immunity with a single-shot.
The scientific team say the new technology may potentially address the issue of waning COVID-19 vaccine immunity, and eliminate the need for repeated booster jabs, particularly for people aged 60 and over, medically vulnerable individuals and their caregivers.
“The results that we see in this study are very promising, and we are confident that the work performed in pre-clinical models is highly translatable to humans,” said Associate Professor Sylvie Alonso, Principal Investigator of this study.
“Indeed, a human equivalent of this immune cell subset exists, and our collaborator, Associate Professor Mireille Lahoud, at Monash University is developing this approach towards future human application.”
Upon a single shot immunisation of the team’s antibody construct, they monitored the immune responses in pre-clinical models over 21 months, and found no signs of declined immunity. In contrast, it was observed that the quality of the immune response (the neutralising antibody response, in particular), was associated with increased protection over time.
The study was published in Molecular Therapy, which is part of Cell Press.
“This study demonstrates the strength of our platform targeting specialised immune cells for vaccine improvement, and exemplifies the power of international research collaborations spanning basic discoveries to translational studies,” said Associate Professor Lahoud.
“There remain many diseases where effective vaccines have proven difficult to generate. Validation of this platform provides strong proof-of-concept for application to such challenges,” she said.
Current Messenger RNA (mRNA) COVID-19 vaccines have been reported to demonstrate peak effectiveness of 62% after three weeks, post-jab, before declining to 9% after nine months. Protection from booster doses has been reported to wane, dropping from 60% one month after the booster dose to 13% at nine months.
“Our teams in NUS Medicine and Monash University foresee that the exceptional durability of the immune responses induced by the Clec9A targeting technology, when used as a booster vaccine strategy, may address the shortcoming of current mRNA vaccines, chief of which is the rapid waning of immune responses,”
Associate Professor Alonso, who is also co-Director of the Infectious Diseases Translational Research Programme at NUS Medicine said.
“We are now evaluating our vaccine candidate as a booster vaccine in mRNA-vaccinated pre-clinical models. We hope to demonstrate that this booster approach will induce long-term protective immunity, and avoid the need of multiple (annual) booster shots.
“Beyond COVID19, this versatile, rapidly-deployable vaccine platform shows promising potential to be part of the pandemic response against diseases caused by unknown pathogens in the future.”
https://medicine.nus.edu.sg/mbio/about-us/our-people/academic-staff/sylvie-alonso.html
Reporting on hot takes from TikTok is considered as news by the SPH presstitutes these days. That's genuinely pathetic.
This is a rumour which needs confirming. Sharing as I receive.
It's with a heavy heart that I share with you the passing of Cheong Gay Eng, Son in Law of SR Nathan this morning. He was out with friends, collapsed suddenly, and could not be revived.”
Another sudden death !
Can someone confirm please?
Iris Koh
t.me/healingthedivide
#obit #funeral 26 Jun 2024 Age 66
Cheong Gay Eng (lawyer)
Husband to Juthika Ramanathan
(Chief Executive of Supreme Court since 1 Feb 2013)
https://www.smu.edu.sg/about/board-trustees/juthika-ramanathan
Son in law to President Nathan
It's with a heavy heart that I share with you the passing of Cheong Gay Eng, Son in Law of SR Nathan this morning. He was out with friends, collapsed suddenly, and could not be revived.”
Another sudden death !
Can someone confirm please?
Iris Koh
t.me/healingthedivide
#obit #funeral 26 Jun 2024 Age 66
Cheong Gay Eng (lawyer)
Husband to Juthika Ramanathan
(Chief Executive of Supreme Court since 1 Feb 2013)
https://www.smu.edu.sg/about/board-trustees/juthika-ramanathan
Son in law to President Nathan
Covid19 already long became common flu, dunno why still got this kind of news in 2024.Meh Meh pak pak
https://australianseniorsnews.com.au/health/new-covid-vaccine-promises-longer-immunity/
New COVID vaccine promises longer immunity
June 5, 2024
Scientists from Monash University and the National University of Singapore have engineered a COVID-19 vaccine that, in pre-clinical models, has shown very long-lasting, protective immunity with a single-shot.
The scientific team say the new technology may potentially address the issue of waning COVID-19 vaccine immunity, and eliminate the need for repeated booster jabs, particularly for people aged 60 and over, medically vulnerable individuals and their caregivers.
“The results that we see in this study are very promising, and we are confident that the work performed in pre-clinical models is highly translatable to humans,” said Associate Professor Sylvie Alonso, Principal Investigator of this study.
“Indeed, a human equivalent of this immune cell subset exists, and our collaborator, Associate Professor Mireille Lahoud, at Monash University is developing this approach towards future human application.”
Upon a single shot immunisation of the team’s antibody construct, they monitored the immune responses in pre-clinical models over 21 months, and found no signs of declined immunity. In contrast, it was observed that the quality of the immune response (the neutralising antibody response, in particular), was associated with increased protection over time.
The study was published in Molecular Therapy, which is part of Cell Press.
“This study demonstrates the strength of our platform targeting specialised immune cells for vaccine improvement, and exemplifies the power of international research collaborations spanning basic discoveries to translational studies,” said Associate Professor Lahoud.
“There remain many diseases where effective vaccines have proven difficult to generate. Validation of this platform provides strong proof-of-concept for application to such challenges,” she said.
Current Messenger RNA (mRNA) COVID-19 vaccines have been reported to demonstrate peak effectiveness of 62% after three weeks, post-jab, before declining to 9% after nine months. Protection from booster doses has been reported to wane, dropping from 60% one month after the booster dose to 13% at nine months.
“Our teams in NUS Medicine and Monash University foresee that the exceptional durability of the immune responses induced by the Clec9A targeting technology, when used as a booster vaccine strategy, may address the shortcoming of current mRNA vaccines, chief of which is the rapid waning of immune responses,”
Associate Professor Alonso, who is also co-Director of the Infectious Diseases Translational Research Programme at NUS Medicine said.
“We are now evaluating our vaccine candidate as a booster vaccine in mRNA-vaccinated pre-clinical models. We hope to demonstrate that this booster approach will induce long-term protective immunity, and avoid the need of multiple (annual) booster shots.
“Beyond COVID19, this versatile, rapidly-deployable vaccine platform shows promising potential to be part of the pandemic response against diseases caused by unknown pathogens in the future.”
https://medicine.nus.edu.sg/mbio/about-us/our-people/academic-staff/sylvie-alonso.html
In order to earn fast fast money, research must also fast fast?
Similar threads
